Objectives: Growth hormone (GH)-deficient individuals display increased adiposity that can be effectively reduced by GH therapy because of GH's lipolytic effects. However, similar GH treatments of individuals with idiopathic obesity (not associated with an endocrinopathy/syndrome) have had little success. We hypothesized that this form of obesity may be associated with GH resistance at the level of the adipocyte because of reduced GH receptor (GHR) expression. Subjects and methods: We studied GHR expression in omental and subcutaneous fat tissues from a cohort of 55 women ranging from lean to obese by various adiposity parameters. mRNA levels of total GHR and the dominant-negative truncated GHR 1À279 (trGHR) form were assayed by quantitative reverse transcriptase-PCR. Associations between adiposity measures and GHR levels as well as trGHR/GHR ratios were analyzed. Results: Total GHR mRNA expression was 2-3-fold lower in omental as well as subcutaneous adipose tissues of obese compared with lean women (Pp0.05-0.001). Lean individuals expressed higher GHR mRNA levels in omental fat compared with subcutaneous (Pp0.01); in obese women, this depot-specific difference was lost. Omental and subcutaneous adipose GHR mRNA levels displayed significant negative correlations with a spectrum of indicators of obesity while, in subcutaneous fat, there was a significantly higher trGHR/GHR ratio with increasing adiposity (Pp0.05). Conclusion: These results support our hypothesis that, with obesity, there is lower GHR expression in the adipocyte, and suggest one possible explanation why GH supplementation is not an effective treatment for individuals with idiopathic obesity.
Introduction
Adipose tissue is a major target of growth hormone (GH) action. This is clear from studies of GH-deficient individuals and patients with defective GH receptors (GHR), all of whom display increased adiposity, and of those suffering from GH excess (acromegaly), who have reduced fat. [1] [2] [3] GHRs are abundantly expressed in human adipocytes where GH has an important role in regulating proliferation and differentiation as well as inducing lipolysis. [4] [5] [6] [7] Clinical and experimental investigations have shown that GH administration leads to the reduction in fat mass in GH-deficient individuals as well as individuals suffering from certain genetic forms of obesity, such as Prader-Willi syndrome, and in obese animal models, such as ob/ob mice, which display diminished GH secretion. [8] [9] [10] [11] However, despite these positive effects of GH on adipose reduction, GH treatments of individuals with idiopathic obesity (not associated with an endocrinopathy or syndrome) have had little success, even though their GH levels are generally reduced. 12 These observations suggest that idiopathic obesity may be associated with GH resistance at the level of the adipocyte because of altered GHR expression.
GHR is a member of the cytokine receptor family; its expression in various tissues is influenced by hormones, nutritional status and developmental processes. 13 In all, 14
GHR mRNA variants with different 5 0 -untranslated regions exist that all code for the same protein. 7, 14 These variants display developmental-and tissue-specific expression profiles: V1, V4, V7 and V8 are specific to postnatal liver whereas the others are expressed ubiquitously. 13, 14 There is a marked increase in total GHR expression during murine and human pre-adipocyte differentiation. 7, 15 There also exist two truncated forms of the GHR protein (trGHR 1À277 and trGHR 1À279 ) that lack a majority of the cytoplasmic domain as a result of normal alternative splicing of the GHR gene. 16 Their expression levels are tissue specific, with trGHR 1À279 being the major form in all human tissues and cell lines examined, including fat. 4, 16 TrGHR proteins interfere with normal full-length receptor signalling in a dominant-negative manner following receptor dimerization. 16 Thus, impaired GH responsiveness in obesity may be attributed to either diminished GHR expression in the adipocytes or increased expression of the truncated form relative to the full-length receptor.
To test these possibilities, we examined levels of total GHR and ratios of trGHR 1À279 /GHR mRNA in omental and subcutaneous adipose depots from a cohort of 55 women, who ranged in body mass index (BMI) from lean to obese. We assessed correlations of a spectrum of adiposity parameters with adipose GHR expression, and compared omental and subcutaneous GHR levels as well as trGHR/GHR ratios in lean vs obese individuals. The results support our hypothesis that there is reduced adipose tissue expression of GHR with increasing obesity.
Subjects and methods

Subjects
A total of 55 women (39.6-61.7 years) undergoing elective abdominal gynecological surgery through the Gynecology Unit of the Laval University Medical Center (Laval, Quebec, Canada) were recruited for this study ( Table 1) . The women had elected for total (n ¼ 53) or subtotal (n ¼ 3) abdominal hysterectomies, some with salpingo-oophorectomy of one (n ¼ 9) or both (n ¼ 19) ovaries. Reasons for surgery included menorrhagia/menometrorrhagia (n ¼ 26), myoma/fibroids (n ¼ 40), incapacitating dysmenorrhea (n ¼ 11), pelvic pain (n ¼ 2), benign ovarian cyst (n ¼ 12), endometriosis (n ¼ 11), adenomyosis (n ¼ 1), pelvic adhesions (n ¼ 4), benign cystadenoma (n ¼ 1), endometrial hyperplasia (n ¼ 5) or polyp (n ¼ 3), and ovarian thecoma (n ¼ 1). Patients with malignancies were excluded. Menstrual status was obtained for 54/55 women while plasma was available for 51 folliclestimulating hormone measurements. In all, 11 women were identified as ovarian hormone deficient, including 6 who had stopped bleeding naturally for at least 4 months and had elevated follicle-stimulating hormone levels (430 IU ml À1 ), 2 who were using a gonadotrophin releasing hormone agonist (leuprolide acetate) and 3 with irregular menstrual bleeding and elevated follicle-stimulating hormone levels. Seven women were using hormonal treatments, including oral contraceptives, hormone replacement or phytoestrogen supplements, and were considered separately. The remaining women (n ¼ 34) were grouped into a premenopausal and perimenopausal group; they had follicle-stimulating hormone values below 30 IU ml À1 and reported the presence of menstrual cycles. It was not possible to distinguish between the premenopausal and perimenopausal status as several women had irregular menses because of their gynecological condition. The majority of the women (n ¼ 45) were classified as having a stable weight, six had lost weight progressively over the previous 5 years and two showed a recent acute weight loss; weight change data were not available for two women. Most frequent medication use included for hypertension (n ¼ 7), thyroid (n ¼ 6), depression (n ¼ 5), hormone replacement therapy (see above) and acid reflux (n ¼ 4). This study was approved by the medical ethics committee of Laval University Medical Center. All subjects provided written consent before inclusion.
Body fat measurements
The women were characterized for BMI (kg m À2 ) and adiposity at the Laval University Medical Center. Total body fat mass, fat-free mass, truncal fat mass and percent total body fat were determined by dual energy X-ray absorptiometry using a Hologic QDR-2000 densitometer and the enhanced array whole-body software V5.73A (Hologic Inc., Bedford, MA, USA). Computed tomography (CT) scans were performed at L2-L3 and L4-L5 vertebral levels to assess crosssectional areas of abdominal fat (GE Light Speed 1.1 CT scanner, GE Medical Systems, Milwaukee, WI, USA). Total, subcutaneous and omental fat were quantified as previously GHR mRNA expression in human obesity A Erman et al described. 17, 18 All measurements were performed on the morning of or within a few days before or after the surgery.
Biochemical measurements
Blood sampling was performed the morning of surgery after a 12 h fasting period to characterize the subjects for a number of biochemical parameters, including total cholesterol, low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol, triglycerides, insulinemia, glycemia, insulin resistance (homeostatic model assessmentinsulin resistance index), leptin, adiponectin, resistin and interleukin-6, as described previously.
17,18
Adipose tissues During surgery, paired adipose tissue samples were collected at the site of surgical incision in the lower abdomen (subcutaneous) and at the distal portion of the greater omentum (omental). 17 Adipocytes were isolated by collagenase digestion. Mean adipocyte diameter, volume, surface area and lipoprotein lipase activity were measured, as previously described. 17, 18 The remaining tissue samples were frozen in liquid nitrogen and stored at À80 1C until extracted for mRNAs. 19 
mRNA quantification
The levels of total GHR and trGHR mRNA were analyzed by a quantitative reverse transcriptase-PCR method, as described previously, 19, 20 0 (antisense)). Target gene quantity was calculated using a comparative Ct method. 20 Amplification efficiencies were validated and normalized to four housekeeping genes: hypoxanthine phosphoribosyltransferase 1, subunit (o) of ATP synthase, glucose-6-phosphate dehydrogenase (G6PD) and 18S. G6PD was selected for the final analysis as it was least influenced by increasing obesity. G6PD was amplified using 5 0 -CAGCGCCTCAACAGCCACAT-3 0 (sense) and 5 0 -AG GCTTCTCCACGATGATGC-3 0 (antisense) primers. 21 
Statistical analysis
Initially the total cohort was assessed for associations between mRNA levels and different adiposity parameters.
Variables normally distributed according to the ShapiroWilks test (Po0.05) were analyzed by Pearson's correlation analysis. Those not normally distributed were log 10 transformed before Pearson's correlation analysis. For variables that could not be normalized, the nonparametric Spearman's rank correlation analysis was performed. For parameters that correlated with both BMI and GHR expression, partial correlations with BMI as a control variable were calculated.
Because there was not a complete set of data for all subjects, certain correlation analyses were n ¼ 48-51 (see legend details). The cohort was then divided into adiposity groups by BMI classification (lean: 18pBMIo25, overweight: 25pBMIo30, and obese: 30pBMIo40). The anthropometric and biochemical characteristics of the overweight and obese groups were compared with the lean controls by parametric one-way analysis of variance or the non-parametric Kruskal-Wallis test followed by Dunnett's group comparison test. Differences in mean GHR mRNA expression or trGHR/GHR ratios between the subcutaneous and omental depots were assessed using the parametric paired sample t-test, following log 10 transformation if necessary. A significance level of Pp0.05 was employed for all tests. Analyses were performed with SPSS software (IBM Corporation, Somers, NY, USA).
Results
Correlations between GHR mRNA levels and adiposity/ biochemical parameters To determine the association between GHR levels and obesity, we initially examined total GHR mRNA expression in the adipose depots from the entire cohort in relation to three hierarchical aspects of adiposity: a measure of total body fat mass (Figure 1 ), an indicator of visceral obesity (L2-L3; Figure 2 ) and a measure of fat cell hypertrophy (adipocyte cell size; Figure 3) , as well as a number of alternate adiposity parameters (Table 2) . In omental depots, total GHR varied over a B3-fold range (Figures 1-3 ) and displayed significant negative correlations with all of the adiposity indicators examined (Pp0.05-0.001; Table 2 ). Total GHR expression in the subcutaneous depots was B2-fold lower (Figures 1-3 ) and presented a significant negative correlation with many obesity parameters (Pp0.05-0.001 ;  Tables 2a and b) ; the association between subcutaneous GHR levels and total or percentage body fat showed a similar trend but did not reach statistical significance (Table 2a , Figure 1 ). These effects were independent of menopausal status, hormone replacement and the use of thyroid medications.
Of the biochemical parameters (Table 2c) , total GHR expression in the two depots displayed significant negative associations with fasting insulin levels and the homeostatic model assessment-insulin resistance index (Pp0.05-0.01). There was a general trend in both depots for a positive correlation of GHR expression with HDL cholesterol and a negative correlation with low-density lipoprotein cholesterol that was highly significant for the omental depots (Pp0.01-0.001). Additionally, we examined the association between adipose tissue GHR mRNA expression with several serum obesity-related adipokines (leptin, adiponectin, resistin and interleukin-6). Only leptin showed a significant negative GHR mRNA expression in human obesity A Erman et al correlation with total GHR in omental (Pp0.001) and subcutaneous (Pp0.01) fat. When partial correlations were calculated for the biochemical parameters that correlated significantly with both BMI and GHR expression, BMI accounted for the correlations of GHR with fasting insulin, homeostatic model assessment-insulin resistance index, low-density lipoprotein cholesterol and leptin. However, the association between HDL cholesterol and omental GHR (Pp0.01) remained significant.
To test the possibility of a dominant-negative receptorinduced GH insensitivity in obesity, we also examined the association of adiposity and biochemical parameters with trGHR/GHR expression ratios. In subcutaneous depots, the trGHR/GHR ratios demonstrated positive correlations that were significant for every adiposity indicator examined except lipoprotein lipase activity (Pp0.05-0.01; Figures  1-3 , Table 2 ). Omental trGHR/GHR ratios displayed a consistently positive, but non-significant, correlation. The trGHR/GHR ratios did not correlate significantly with any of the biochemical parameters (Table 2c) .
Depot-specific differences in GHR mRNA expression in lean vs overweight vs obese subjects To determine at what adiposity level interdepot differences in GHR expression and trGHR/GHR ratios became 
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A Erman et al significant, we divided the cohort into groups of lean, overweight and obese subjects by the clinically relevant BMI criteria (Table 3 , Figure 4 ). The mean age, blood pressures, glucose, total cholesterol or low-density lipoprotein cholesterol levels of the overweight and obese groups were not significantly different from the lean control. In addition, there were no significant differences amongst the groups because of individual menopausal state, weight stability or medication use. However, as expected, BMI, body fat mass, percent body fat, homeostatic model GHR mRNA expression in human obesity A Erman et al assessment-insulin resistance index, insulin, triglyceride and leptin levels displayed significant differences in both the overweight and obese groups compared with the lean group (Pp0.05-0.001). HDL cholesterol, resistin and adiponectin levels were significantly different only in the obese (Pp0.05).
Total GHR mRNA levels were significantly higher in omental vs subcutaneous fat from both the lean (Pp0.01) and overweight groups (Pp0.001); in contrast, obese individuals exhibited no significant interdepot differences (Figure 4) . TrGHR/GHR ratios were significantly higher in the subcutaneous vs omental tissues of the overweight and obese groups (Pp0.05-0.001).
Discussion
GH treatment of GH-deficient individuals has been very successful in decreasing their obesity, especially visceral, and improving lipid profiles: GH treatment results in decreased adipocyte size and lipid content. 8, 9, 11 GH is also thought to increase b-adrenergic receptors and, thus, to increase sensitivity to catecholamines, the end result of which is to enhance cAMP-mediated activation of hormone-sensitive lipase and to decrease lipoprotein lipase expression.
5,22
Because of these profound effects of GH on adipose tissue, it would seem logical to use this lipolytic/antilipogenic hormone to treat general obesity. Unfortunately, GH has had inconsistent effects when used for idiopathic obesity, even though these individuals display reduced serum GH levels due to decreased secretion and increased clearance. A recent meta-analysis of 24 clinical trials (1987-2007) of GH therapy for idiopathic obesity in adults concluded that GH has only small beneficial effects on body composition and lipid profiles, and does not lead to a significant weight loss even with supra-physiological doses.
12
To understand the reasons for the relative ineffectiveness of GH in this obese population, we asked whether obesity was associated with altered GHR expression in adipose tissues. Indeed, in the present study of a cohort of women, we found that adipose GHR mRNA levels are 2-3-fold lower 
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A Erman et al in both omental and subcutaneous fat depots and display significant negative correlations with a spectrum of obesity parameters. In contrast, we observed significant positive correlations between subcutaneous trGHR/GHR ratios and adiposity. Finally, we report that whereas lean individuals express higher GHR levels in omental compared with subcutaneous fat, in the obese, this depot-specific difference is lost.
Indicators of GH sensitivity in obesity
Although these data supported our hypothesis, they were somewhat surprising, as previous studies of obese populations have concluded that, despite the decrease in serum GH, there was evidence for increased GHR in target tissues. Two groups 23, 24 have reported a positive correlation between obesity and the serum levels of GH-binding protein (GHBP), the extracellular cleavage product of both full-length GHR and trGHR. 16 In addition, others have reported normal levels of serum insulin-like growth factor I (IGF-I) as well as enhanced IGF-I responses to GH administration with obesity. 25, 26 However, studies in lean people have shown that GHBP levels are negatively associated with omental adipose expression of GHR and trGHR, 27 while Johannsson et al. 28 found a negative correlation between serum GHBP levels and GH responsiveness in GH-deficient adults. It is possible that the increased levels of circulating GHBP and IGF-I response to GH in obesity may be because of generation of GHBP and IGF-I by alternate GH target tissues, most likely the liver, as it is the major source of circulating IGF-I in response to GH stimulation. 22 The human GHR gene is regulated by both liver-specific and ubiquitous promoters, 14 making it possible for GHR expression to be influenced differently in liver and adipose tissues during obesity.
Relationship between obesity and GHR expression Because of the cross-sectional nature of this study, we cannot acertain the cause and effect nature of the relationship between GHR expression and obesity. However, whereas no human studies have looked at the effects of weight reduction on GHR levels, two microarray studies of murine white adipose tissues have reported an upregulation of GHR mRNA following diet-related fat loss. 29, 30 Thus, changes in GHR expression reported in our study are likely to be a consequence of obesity. Several mechanisms could explain the significantly lower expression of GHR in obese adipose tissues. GH has been reported to positively regulate GHR expression in many target cells, including adipocytes; 6,31 the decline in serum GH with obesity 12 could modulate GHR gene transcription in the adipocyte. However, if this was true, one would expect GH replacements to improve GHR levels. Unfortunately, the only clinical studies examining this possibility are limited to GH treatment of adults who are GH deficient or who have Prader-Willi syndrome and these have produced contradictory results. 11, 27 Another explanation is that GHR suppression is a pathological consequence of obesity. 32 With increasing obesity, adipose tissue displays markedly abnormal adipocyte hypertrophy and activity, including increased production of pro-inflammatory cytokines (for example, interleukin-6, interleukin-1b and tumor necrosis factor-a), fatty acids and intracellular cortisol, which may alter GHR expression. [33] [34] [35] [36] [37] Differences in GHR expression between omental and subcutaneous adipose depots We found in the present study that lean individuals express significantly higher levels of GHR mRNA in the omental vs subcutaneous adipose tissues. Many differences in the metabolic activities of the two depots have been documented, including adipocyte sensitivity to lipolytic signals other than GH, such as catecholamines. 35 Enhanced visceral catecholamine sensitivity in the lean has been attributed to the elevated expression of pro-lipolytic b-adrenergic receptors in omental depots and the higher expression of antilipolytic a 2 -adrenergic receptors in subcutaneous fat. 38 Interestingly, GH administration to GH-deficient individuals improves visceral catecholamine responsiveness via the upregulation of b-adrenergic receptors. 39 Taken together, these data suggest a mechanism by which GH may normally affect a more rapid lipolysis in omental vs subcutaneous tissues. 8, 9, 11 In addition, we found that the negative relationship between obesity and total GHR expression is stronger in omental vs subcutaneous tissues. This may be because of differences in the immediate micro-environment of these tissues during obesity. 35, 37, 38, 40 In contrast, trGHR/GHR ratios have significant positive associations with obesity only in the subcutaneous depots, suggesting that dominantnegative effects may influence GH signalling in this depot.
Relationship between GHR expression and HDL levels
We found a significant positive relationship between HDL cholesterol and adipose tissue GHR expression independent of BMI. The majority of studies of GH-deficient patients have found significant improvements in HDL levels following GH replacement. [41] [42] [43] Although the positive effects are usually related to GH-induced improvements in adiposity and blood lipids, two studies of female subjects free of GH-related disorders found a positive correlation between basal GH levels and HDL cholesterol, which was independent of BMI, IGF-I or insulin. Thus, the data at present generally support the concept that GH signalling can influence HDL cholesterol levels although the mechanism remains unknown.
44,45
Conclusions
Three issues should be addressed in future investigations. First, males should also be studied, as there are likely to be GHR mRNA expression in human obesity A Erman et al gender differences. Second, GHR analyses of the different adipose cell subpopulations should be included to investigate interdepot differences. Third, the GHR mRNA analyses should be paralleled by protein assays; present limitations are because of small tissue samples obtainable at surgery, the low level of GHR protein in human tissues and the low potency of available human GHR antibodies that necessitates an immunoprecipitation step before western blotting and, thus, requires a large amount of tissue. 46 In summary, GH therapy for idiopathic obesity has been generally disappointing. 12 Results of the present study suggest one reason: a much lower expression of GHR in obese adipose depots. Thus, GH treatment of obese individuals is likely to remain ineffective unless coupled with treatments that can improve adipose-specific GH responsiveness. It will now be important to identify the mechanisms involved in regulating the major ubiquitous GHR promoters as well as the alternative splicing process in adipose tissues.
